Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.37 |
| ▸ | F3 | P13726 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 3/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765764 | 0.90 | CMA1 (0.40) | CMA1CTRCNAMPT | |
| SCHEMBL30765579 | 0.89 | F3 (0.39) | F2F3PRSS1NTRK1CMA1 | |
| SCHEMBL30765494 | 0.88 | F3 (0.34) | F2F3PRSS1CMA1CASP1 | |
| SCHEMBL30766011 | 0.88 | CMA1 (0.33) | F2KMT2ANTRK1CMA1CASP1 | |
| SCHEMBL30765846 | 0.87 | CMA1 (0.38) | CMA1CTRC | |
| SCHEMBL30765604 | 0.87 | AVPR1B (0.34) | F2CMA1CASP1KDRNAMPT | |
| SCHEMBL30765845 | 0.86 | TDP1 (0.36) | F2F3KMT2ACMA1CASP1 | |
| SCHEMBL31558548 | 0.84 | KDR (0.33) | F2F3PRSS1KDRNAMPT | |
| SCHEMBL30765643 | 0.83 | NAMPT (0.35) | F2F3HDAC6NAMPT | |
| SCHEMBL30765465 | 0.83 | LMNA (0.39) | KMT2AHDAC6CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |